
Sardopa250 mg
Incepta Pharmaceuticals Ltd.
Methyldopa is a centrally-acting antihypertensive agent (alpha-2 adrenergic agonist) approved for the treatment of hypertension.
Methyldopa is a centrally-acting antihypertensive agent (alpha-2 adrenergic agonist) approved for the treatment of hypertension. Its evidence-based uses include:
Methyldopa is not indicated for hypertensive emergencies requiring rapid blood pressure reduction.
| Phase | Dose |
|---|---|
| Initial (first 48 hours) | 250 mg two to three times daily |
| Titration | Increase as needed at intervals of at least 2 days |
| Maintenance | 500 mg to 2 g daily in 2-4 divided doses |
| Maximum | 3 g per day |
| Combined with other antihypertensives | Limit initial dose to 500 mg daily in divided doses; adjust concomitant drug dose accordingly |
Initial dose: 10 mg/kg body weight per day in 2-4 divided doses, adjusted at intervals of at least 2 days until adequate blood pressure control is achieved. Maximum dose: 65 mg/kg or 3 g per day, whichever is less.
Patients with reduced renal function may be more sensitive to the antihypertensive effect and may respond to lower doses; dose should be individualized with careful monitoring of blood pressure.
Methyldopa may be taken with or without food and should be taken at the same time(s) each day. Doses should not be skipped or doubled.
Common and important adverse effects of Methyldopa include:
Methyldopa is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.